Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine.
In: AIDS Research & Therapy, Jg. 21 (2024-01-03), Heft 1, S. 1-6
Online
academicJournal
Zugriff:
We assessed whether the impact of cabotegravir plus rilpivirine on inflammation reduction differs from that of oral antiretrovirals, using real-world data. Inflammatory biomarkers and lipid profiles were followed from baseline to 8 months after switching. Seventy-eight participants were analyzed. The CD4/CD8 ratio and C-reactive protein did not change. There were transient decreases in CD8 and CD4 counts in the group that switched from the dolutegravir-based regimen, but not in the tenofovir alafenamide-based regimen group. High-density lipoprotein (HDL) cholesterol increased, resulting in a decrease in the total-cholesterol to HDL cholesterol ratio, whereas there was no significant change in low-density lipoprotein cholesterol. [ABSTRACT FROM AUTHOR]
Copyright of AIDS Research & Therapy is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine.
|
---|---|
Autor/in / Beteiligte Person: | Adachi, Eisuke ; Saito, Makoto ; Otani, Amato ; Koga, Michiko ; Yotsuyanagi, Hiroshi |
Link: | |
Zeitschrift: | AIDS Research & Therapy, Jg. 21 (2024-01-03), Heft 1, S. 1-6 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 1742-6405 (print) |
DOI: | 10.1186/s12981-023-00590-4 |
Schlagwort: |
|
Sonstiges: |
|